Core Viewpoint - A class action lawsuit has been filed against Bakkt Holdings, Inc. for allegedly misleading investors about the stability and diversity of its crypto services revenue, particularly its reliance on a single contract with Webull [1][2]. Group 1: Allegations and Financial Impact - The complaint alleges that Bakkt misrepresented the stability and diversity of its crypto services revenue and failed to disclose its substantial dependence on a single contract with Webull [2]. - Bakkt disclosed that Webull accounted for 74% of its crypto services revenue for the nine months ending September 30, 2024, and that 98% of its total revenue came from crypto services during the same period [3]. - Following the announcement of Webull's termination of their commercial agreement, Bakkt is expected to face a 73% loss in top-line revenue, leading to a significant drop in share price by $3.50 or 27.3% to close at $9.33 per share on March 18, 2025 [3]. Group 2: Legal Proceedings and Participation - Shareholders are encouraged to participate in the class action against Bakkt Holdings, with options to serve as lead plaintiff or remain an absent class member [4]. - Robbins LLP operates on a contingency fee basis, meaning shareholders will incur no fees or expenses for representation [5].

Core Viewpoint - A class action lawsuit has been filed against Treace Medical Concepts, Inc. for allegedly misleading investors about the demand for its primary product, the Lapiplasty 3D Bunion Correction System, leading to a significant decline in stock price [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Treace Medical failed to disclose competition affecting the demand for its primary product, resulting in a revenue decline [2]. - Following the revelation of these issues, Treace Medical's stock price dropped nearly 63%, closing at $4.17 per share on May 8, 2024 [2]. Group 2: Class Action Participation - Shareholders may be eligible to participate in the class action, with a deadline to file as lead plaintiff by June 10, 2025 [3]. - Shareholders can choose to remain absent class members without participating in the case [3]. Group 3: Company Background - Treace Medical Concepts, Inc. focuses on advancing surgical management standards for bunion and related midfoot deformities [1].

Core Viewpoint - A class action has been filed against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC, and Pfizer, alleging violations of the Securities Exchange Act of 1934 related to misleading investors during a secondary stock offering and subsequent merger announcement [1][2][3]. Group 1: Allegations and Impact - The complaint claims that Cerevel's secondary offering documents omitted material facts about AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share, which artificially deflated Cerevel's stock price until the merger was announced [2]. - Bain Capital, as Cerevel's controlling shareholder, allegedly purchased shares at the depressed price while possessing nonpublic information about AbbVie's acquisition interest, leading to a windfall of over $120 million when AbbVie agreed to acquire Cerevel for $45 per share [2]. - The action also seeks damages for investors who held shares as of January 8, 2024, due to misleading statements in Cerevel's January 18, 2024 Proxy statement regarding the nature and timing of AbbVie's interest [3]. Group 2: Legal Proceedings - Shareholders interested in serving as lead plaintiffs must file their papers by June 3, 2025, with the lead plaintiff representing other class members in the litigation [4]. - Shareholders do not need to participate actively in the case to be eligible for recovery, allowing them to remain absent class members if they choose [4].

Core Points - A class action has been filed against Treace Medical Concepts, Inc. for allegedly misleading investors regarding the demand for its primary product, the Lapiplasty 3D Bunion Correction System [1][2] - The complaint states that competition negatively impacted the demand and utilization of the Lapiplasty system, leading to a decline in Treace Medical's revenue [2] - Following the revelation of these issues, Treace Medical's stock price dropped nearly 63%, closing at $4.17 per share on May 8, 2024 [2] Company Overview - Treace Medical Concepts, Inc. focuses on advancing surgical management standards for bunion and related midfoot deformities [1] - The company is under scrutiny for its failure to disclose critical information regarding competition and product demand [2] Legal Proceedings - Shareholders interested in serving as lead plaintiffs must file their papers by June 10, 2025 [3] - Participation in the class action is not mandatory for recovery; shareholders can remain absent class members [3] Firm Background - Robbins LLP is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4]

Core Viewpoint - Class actions have been initiated on behalf of stockholders of Solaris Energy Infrastructure, Actinium Pharmaceuticals, Bakkt Holdings, and Cerevel Therapeutics, with specific allegations of misleading statements and omissions of material facts regarding their business operations and prospects [1]. Solaris Energy Infrastructure, Inc. (NYSE: SEI) - Class period is from July 9, 2024, to March 17, 2025, with a lead plaintiff deadline of May 27, 2025 [2]. - Allegations include failure to disclose that Mobile Energy Rentals LLC had minimal corporate history, lacked a diversified earnings stream, and was co-owned by a convicted felon associated with turbine-related fraud [2]. - Claims that Solaris overstated commercial prospects from an acquisition and inflated profitability metrics by not properly depreciating turbines, leading to materially misleading statements [2]. Actinium Pharmaceuticals, Inc. (NYSE: ATNM) - Class period is from October 31, 2022, to August 2, 2024, with a lead plaintiff deadline of May 26, 2025 [3]. - The complaint alleges that Actinium made false claims regarding the strength of data submitted to the FDA for its Biologics License Application for Iomab-B, later admitting the need for additional clinical trials [3]. - Public statements were deemed materially misleading, resulting in investor damages when the truth was revealed [3]. Bakkt Holdings, Inc. (NYSE: BKKT) - Class period is from March 25, 2024, to March 17, 2025, with a lead plaintiff deadline of June 2, 2025 [4]. - Allegations include misrepresentation of the stability and diversity of crypto services revenue, which was heavily reliant on a single contract with Webull [4]. - Positive statements about the company's business were claimed to be materially misleading due to undisclosed dependencies [4]. Cerevel Therapeutics Holdings, Inc. (CERE) - Class period is from October 11, 2023, to August 1, 2024, with a lead plaintiff deadline of June 3, 2025 [6]. - The complaint alleges that Cerevel's offering documents omitted material facts about AbbVie's interest in acquiring the company at a significantly higher price than the offering price of $22.81 per share [6]. - Claims that Cerevel's controlling shareholder acquired shares at an artificially depressed price while possessing nonpublic information, leading to a substantial windfall when AbbVie announced the acquisition at $45 per share [6][7].

Core Viewpoint - A class action lawsuit has been filed against The Trade Desk, Inc. for allegedly misleading investors about its business prospects during a specific period [1][2]. Group 1: Allegations and Challenges - The lawsuit claims that The Trade Desk failed to disclose significant execution challenges related to the rollout of its new platform, Kokai, which affected client transitions from the older platform, Solimar [2]. - These execution challenges reportedly delayed the Kokai rollout and negatively impacted the company's business operations and revenue growth [2]. - The positive statements made by the company regarding its business and prospects were deemed materially false and misleading due to these undisclosed issues [2]. Group 2: Financial Performance - On February 12, 2025, The Trade Desk reported fourth quarter revenue of $741 million, which was below its guidance of $756 million and analysts' expectations of $759.8 million [3]. - The company's revenue guidance for the first quarter of 2025 was at least $575 million, missing analysts' estimates of $581.5 million [3]. - Following the announcement of these results and the acknowledgment of the slower Kokai rollout, the stock price dropped by $40.31, or over 32%, from $122.23 to $81.92 per share [3]. Group 3: Class Action Participation - Shareholders interested in participating in the class action must file their papers by April 21, 2025, to serve as lead plaintiffs [4]. - Shareholders can remain absent class members if they choose not to participate in the case [4]. Group 4: Company Background - Robbins LLP is noted as a leader in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [5].

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired ModivCare, Inc. (NASDAQ: MODV) securities between November 3, 2022, and September 15, 2024, alleging that the company misled investors regarding its business prospects [1][2]. Allegations - The complaint states that ModivCare failed to disclose that certain contracts in its Non-Emergency Medical Transportation (NEMT) segment led to a deterioration in the company's free cash flow [2]. - As a result of these undisclosed issues, the company experienced negative impacts on adjusted EBITDA due to contract renegotiations and pricing accommodations, and it faced liquidity challenges [2][3]. - The positive statements made by the company regarding its business operations and prospects were deemed materially misleading and lacked a reasonable basis [2][3]. Legal Proceedings - Shareholders interested in serving as lead plaintiffs in the class action must file necessary documents with the court by March 31, 2025 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. Company Background - Robbins LLP is recognized for its leadership in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [5].

Core Viewpoint - A class action lawsuit has been filed against The Trade Desk, Inc. for allegedly misleading investors about its business prospects during a specific period, particularly regarding the rollout of its new platform, Kokai [1][2]. Group 1: Allegations and Challenges - The lawsuit claims that The Trade Desk failed to disclose significant execution challenges related to the Kokai rollout, which included difficulties in transitioning clients from the older platform, Solimar [2]. - These execution challenges reportedly delayed the Kokai rollout and negatively impacted the company's business operations and revenue growth [2]. - The positive statements made by the company regarding its business and prospects were deemed materially false and misleading due to these undisclosed challenges [2]. Group 2: Financial Performance - On February 12, 2025, The Trade Desk reported fourth quarter revenue of $741 million, which was below its guidance of $756 million and analysts' estimates of $759.8 million [3]. - The company's revenue guidance for the first quarter of 2025 was at least $575 million, missing analysts' expectations of $581.5 million [3]. - Following the announcement of these results and the acknowledgment of the slower Kokai rollout, the stock price dropped by $40.31, or over 32%, from $122.23 to $81.92 per share [3].